블로그
- [Philippines FDA] FDA Advisory No.2026-0704 || Public Health Warning Against the Purchase and Use of FDA Advisory No.2026-0704 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “Jinling® 777 Piyan Ping® Ointment 20g” Updated: 2026-07-06 The Food and Drug Administration (FDA
- 외신이 본 한국과 주요 뉴스(260704) dockey=600-202607010700BIZWIRE_USPRX____20260701_BW576499-1 셀트리온, 항체-약물 접합체(ADC) 항암 신약 후보물질 ‘CT-P71’ 미국 FDA 패스트트랙 지정 https://www.oncologynewscentral.com/drugs/info/oncology-drugs-fast-tracked-by-the-fda-in-may-and-june
- [Philippines FDA] FDA Advisory No.2026-0708 || INFORMATION ON BLEACH POISONING PREVENTION FDA Advisory No.2026-0708 || INFORMATION ON BLEACH POISONING PREVENTION Updated: 2026-07-01 Proclamation The Food and Drug Administration (FDA) thus provides information to the general public on the proper
- HLB 간암신약 FDA 결정 임박 HLB 간암신약 FDA 결정 임박…세 번째 도전 최대 변수는 CMC 23일 허가 결정 예정…임상 경쟁력은 입증 승인 시 미국 진출·기업 신뢰 회복 기대 한용해 HLB그룹 CTO 겸 주제로 강연하고 있다. 2024.4.25 HLB(028300)의 간암 신약 '리보세라닙·캄렐리주맙' 병용요법에 대한 미국 식품의약국(FDA)의 허가 결정이 이달 중 내려진다.
- [Philippines FDA] FDA Advisory No.2026-0707 || QUALITY HOLD ON ALL BATCHES OF NICARDIPINE HYDROCHLOR FDA Advisory No.2026-0707 || QUALITY HOLD ON ALL BATCHES OF NICARDIPINE HYDROCHLORIDE 1 mg/ml SOLUTION Updated: 2026-06-30 In the interest of public health and safety, the Food and Drug Administration (FDA
- [Philippines FDA] FDA Advisory No.2026-0667 || Public Health Warning Against the Purchase and Use of FDA Advisory No.2026-0667 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “Sebo de Macho” Updated: 2026-06-24 The Food and Drug Administration (FDA) advises the public
- [U.S. FDA] FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with R This approval marks the first FDA-approved treatment for this indication and represents an important "The FDA recognizes the large unmet need in patients with type 1 diabetes," said Acting Asso.......
- [Philippines FDA] FDA Advisory No.2026-0620 || Public Health Warning Against the Purchase and Use of FDA Advisory No.2026-0620 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “Dok-Apo Miracle Healing Lotion” Updated: 2026-06-05 The Food and Drug Administration (FDA)
- [Philippines FDA] FDA Advisory No.2026-0624 || Public Health Warning Against the Purchase and Use of FDA Advisory No.2026-0624 || Public Health Warning Against the Purchase and Use of the Unregistered Drug Product “J-CAIN Cream (Lidocaine) 59.9% 500g” Updated: 2026-06-05 The Food and Drug Administration (FDA
- 다이어트 주사 마운자로(Tirzepatide)의 수면무호흡증 치료제로서의 3가지 핵심 메커니즘과 임상 증거. 부산 기장 정관 급여 비급여 원내 원외 처방 *코엔이비인후과* 오늘 소개해 드릴 논문은 저명한 의학 저널 Frontiers in Medicine에 게재된 종합 리뷰로, 티르제파티드가 어떻게 수면무호흡증을 개선하는지 그 복합적인 작동 원리와 실제 이 약은 이미 뛰어난 체중 감량 효과로 전 세계적인 주목을 받고 있는데요, 2024년 6월 미국 식품의약국(FDA)은 티르제파티드를 '비만 관련 폐쇄성 수면무호흡증(OSAS)' 치료제로